Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in Japanese participants with Stage 2 type 1 diabetes
jRCT2031240637Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of teplizumab in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Sanofi. Primary endpoints: Number of participants with Stage 3 type 1 diabetes, Change from baseline in AUC of C-peptide and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2031240637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240637.